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         Jeremy Martinson, DPhil. 
Background - The Martinson Lab is examining genetic characteristics related to cardiovascular 
disease (CVD) in men with HIV undergoing HAART therapy that are enrolled in the Multicenter 
Aids Cohort Study (MACS).  CVD is a major side effect of HIV infection and HAART therapy.  
While the mechanism behind this remains unknown, the folic acid metabolic pathway may be 
involved.   This study examines genes that encode enzymes involved in this pathway.  
Polymorphisms in these genes may lead to increased risk of CVD due to altered function of the 
enzymes they encode.  The following polymorphisms in the MTHFR, MS, and MTRR genes 
have been found to affect enzymatic function of Methylenetetrahydrofolate reductase (MTHFR), 
Methionine Synthase (MS or MTR), and Methionine Synthase Reductase (MTRR) respectively: 
MTHFR C677T, MTHFR C1068T, MS A2756G and MTRR A66G.  SNP genotypes for these 
loci were characterized for the MACS DNA samples.  These results were compared with 
corresponding clinical data and statistics were used to determine how polymorphisms affect 
cardiovascular disease when influenced by HIV infection and HAART therapy.  Methods – 
MACS DNA samples were amplified using PCR, and each SNP was characterized using a 
Fluorescence Polarization Assay (FP).  These data and clinical data for LDL, HDL, triglyceride, 
BMI, HIV status, HAART status, age, gender, and family history were analyzed using box-and-
whisker diagrams, Kruskal-Wallis test, odds ratio calculations, and logistic regression analysis.  
Results – Visual trends were seen between LDL levels and polymorphisms in MTHFR C1068T 
and MS A2756G.  However, no significant associations were found statistically between SNP 
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genotypes and LDL levels.  A protective association may exist between the MS A2756G GG 
genotype and not-high LDL levels, but the small sample size of this genotype means that 
statistical significance was not reached.  We intend to obtain data for more samples and repeat 
statistical calculations.  This may lead to statistically significant outcomes.  This thesis 
contributes to public health by furthering knowledge of how an individual’s genetics influences 
CVD risk while being HIV+ and undergoing HAART therapy.  This knowledge enables the 
patient to be given the best care possible with regards to their individual situations.    
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1.0  INTRODUCTION 
1.1 THE PROBLEM 
For many years, an association has been observed between some HIV-infected 
individuals undergoing highly active anti-retroviral therapy (HAART) and the risk of 
cardiovascular disease [1].  This risk is characterized by increased prevalence of a high risk 
atherogenic phenotype.  An atherogenic phenotype is illustrated by abnormally high levels of 
triglycerides and low density lipoproteins (LDLs), and abnormally low levels of high density 
lipoproteins (HDL).  Premature atherosclerosis has been observed to result in a subset of 
individuals with the high risk atherogenic phenotype, as well as insulin resistance, central fat 
accumulation, and peripheral fat wasting [2, 3].  These associations generate concern for the long 
term ramifications of HAART therapy on various individuals.  We think that genetic factors may 
be involved in the development of a high risk atherogenic phenotype.  If genetics determines the 
amount of risk a certain individual has of developing cardiovascular disease, they can be tested 
when HAART is initiated and carefully monitored so that the disease does not develop [4].    
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1.2 THE IMPACT OF HIV ON LIPIDS  
HIV is a virus that wreaks havoc on the lipid metabolism of its host.  HIV positive 
individuals not undergoing therapy have a higher prevalence of metabolic diseases, such as 
hypertriglyceridaemia, impaired glucose tolerance, and high plasma triglyceride concentration, 
than those who are not infected with HIV [5].  Highly active anti-retroviral therapy (HAART) 
has been shown to further exacerbate these conditions in individuals where they are already 
present [6].   
The complex interactions between the HIV virus, HAART, and environmental and 
genetic factors from the host may all play an integral part in the development of cardiovascular 
disease [6].  The HIV virus relies on the presence of cholesterol-dense structures known as lipid 
rafts in the host cell membrane in order to negotiate its entry from the extra cellular matrix into 
the cell [7].  The exact mechanisms are not known, but it is hypothesized that HIV may 
manipulate the body’s lipids to enable cell entry.  One proposed theory for HAART’s 
contribution to cardiovascular disease is that long term effects of HAART therapy include 
endothelial oxidative stress, which causes attraction and activation of mononuclear cells.  The 
congestion of these cells in the arteries contributes to atherosclerosis, and thus cardiovascular 
disease [8].  We think that genetic and environmental factors of the host, which influence 
development of cardiovascular disease in the non-HIV positive population, also contribute to 
cardiovascular disease in the HIV positive population.       
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1.3 HAART THERAPY 
HAART typically involves prescribing a combination of three antiretroviral drugs that 
function in reducing plasma levels of HIV RNA.  These drugs fall into the three main categories 
of nucleoside reverse transcriptase inhibitors (NRTIs), non nucleoside reverse transcriptase 
inhibitors (NNRTIs), and protease inhibitors (PIs).  These drugs inhibit replication of HIV by 
competitive inhibition, non-competitive inhibition, and enzymatic inhibition, respectively.  
NRTIs are analogs of adenine, cytosine, guanine, and thymine that compete with normal 
nucleotides for access to binding sites on the HIV RNA template and thus cause defective RNA 
to be produced by HIV reverse transcriptase.  NNRTIs are non-competitive inhibitors, and they 
are designed to bind to a site on the reverse transcriptase enzyme that is not directly involved in 
template binding, but which also inhibits HIV replication from occurring.  Protease inhibitors 
deactivate the HIV enzyme protease, which functions in processing the new strands of HIV 
polyprotein so that they can form new virus particles and increase plasma RNA levels [9].  The 
overall effects of HAART therapy are to decrease viral load in the blood, semen, vaginal 
secretions, and to increase the number of CD4 T cells in the body.  Since these effects contribute 
to maintaining a stronger immune system, HAART decreases the amount of opportunistic 
infections suffered by HIV positive individuals [10].   
The Office of AIDS Research Advisory Council suggests that HAART therapy should be 
administered to any HIV+ individual with a CD4 T cell count of 350 cells/mm3 or less [11].  
Once an individual begins taking the therapy, it is essential that the medication is taken on time 
as prescribed.  If timelines are disregarded or a dose is skipped, resistance to the drugs may 
develop.  If this occurs, stronger medications must be prescribed.  Some medications cause side 
effects such as myalgia, rash, nausea, vomiting, and diarrhea, among others.  Resistance to 
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milder drugs should be avoided at all costs by taking medications as prescribed.  It is not ideal to 
switch a patient to a stronger drug with more severe side effects if it is not necessary [11].   
1.4 CARDIOVASCULAR DISEASE 
As previously mentioned, Cardiovascular Disease (CVD) is a common side effect of 
HAART.  In the HIV negative United States population, CVD is the most common cause of 
death independently in each state, and is also responsible for 40% of total deaths, nationwide 
[12].  It is characterized by heart attack, angina, heart failure and arrhythmias.  These symptoms 
are caused by atherosclerosis, or hardening and narrowing of the blood vessels due to blockages 
of lipids and cellular debris that prevent sufficient amounts of blood from getting to the heart and 
brain [13].  Since CVD is such a major concern in the general HIV negative population, studies 
have been performed in attempts to identify genes and environmental factors that affect the 
pathogenesis of the disease.  The folic acid metabolic pathway and specific genes may influence 
CVD  susceptibility in this pathway [14].    
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Figure 1. Folate Metabolic Pathway: essential genes and enzymes involved in the metabolic pathway 
[15] 
1.5 FOLIC ACID METABOLIC PATHWAY 
The folic acid metabolic pathway results in two main processes: DNA methylation and 
purine production for DNA synthesis (Figure 1).  The DNA methylation process has been our 
main focus due to the association that has been shown between inadequate DNA methylation and 
risk of cardiovascular disease [14], although the precise relationship between folate metabolism 
and cardiovascular disease remains unclear.  As shown in Figure 1, methyl groups are produced 
through the enzymatic metabolism of the amino acid homocysteine.  These methyl groups are 
used to methylate the cytosine-5 region of genomic DNA, which is essential for DNA stability, 
chromatin structure, and in controlling transcription, or the “turning on and off” of genes [14].  
The following enzymes, named after the gene from which they are produced, catalyze the DNA 
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methylation function of the folic acid metabolic pathway and will be discussed later: 
Methylenetetrahydrofolate reductase (MTHFR), Methionine Synthase (MS), and Methionine 
Synthase Reductase (MTRR). 
 A second essential function of the methylation process of the folic acid metabolic 
pathway is the conversion of homocysteine into methionine.  This step is very important, as 
excess levels of homocysteine are toxic to the body and have been associated with vascular 
complications [16, 17].  A possible explanation, called the homocysteine-thiolactone hypothesis, 
has been proposed to explain why this occurs.  This proposal suggests that genetic 
polymorphisms or insufficient concentrations of folate, vitamin B6, or vitamin B12, can cause 
excess levels of homocysteine to be present in the body.  These factors disrupt the folic acid 
metabolic pathway shown in Figure 1 and the homocysteine is, instead, directed towards an 
alternate biochemical pathway where it is converted into homocysteine-thiolactone, which is 
then converted into an N-homocysteine protein.  This protein elicits an autoimmune response, 
cell death, and inflammation, which in turn, directly cause atherosclerosis and cardiovascular 
problems [17].  The folate metabolic pathway is very complex, however, and it is not known 
which of these variables directly affects cardiovascular disease.  We plan to analyze genetic 
factors that are involved in different parts of the pathway, hoping that it will help reveal the 
precise factors that contribute to cardiovascular disease.     
1.6 SINGLE NUCLEOTIDE POLYMORPHISMS 
Single nucleotide polymorphisms (SNPs) are genetic variations in a gene involving a 
single nucleotide change at a particular location on the gene sequence.  Typically there are two 
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variations.  The more common variant is called the major allele, and the least common variant is 
called the minor allele [18].  SNP nomenclature involves a number encased by two uppercase 
letters.  The number is typically the nucleotide’s position within the gene.  The first letter 
indicates the major allele in the population of the SNP discovery and the second letter indicates 
the minor allele.  In order for a single-base mutation to be classified as a SNP, the minor allele 
must occur in at least 1% of the population [18].   SNPs in a gene can have negative 
ramifications.  If a certain variation occurs during transcription that causes a protein’s translation 
to be terminated early, the protein will be defective and will not be able to fulfill its biochemical 
purpose.  For example, a mid-protein amino acid could undergo a SNP mutation in transcription 
that changes it into a stop codon, therefore terminating translation of the protein prematurely.  It 
is thought that the SNPs in this study reduce the functional ability of the enzymes previously 
mentioned, therefore causing a higher risk of CVD.  The following SNPs were genotyped:  
MTHFR C677T, MTHFR C1068T, MS A2756G, and MTRR A66G.  These SNPs were chosen 
because the literature identifies them as being SNPs associated with high risk of diseases 
resulting from folate metabolism dysfunction [19].  
1.6.1 MTHFR 
The gene MTHFR, encoding the enzyme Methylenetetrahydrofolate reductase, is located 
on chromosome 1, and is 19,322 base pairs long. The enzyme product specifically reduces the 
molecule 5,10-methylenetetrahydrofolate (methylene-THF) to 5-methyltetrahydrofolate (methyl-
THF) [15, 20].  The product of this reaction is a methyl group which is necessary for the 
conversion of homocysteine to methionine.  It also contributes to the production of purines for 
DNA synthesis in conjunction with the enzymes MS and MTRR [20].  It has been hypothesized 
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that in the presence of certain SNPs, dysfunctional enzyme is produced and homocysteine is 
therefore inefficiently detoxified.  Consequently, the risk of cardiovascular disease, neural tube 
defects, colon cancer and acute leukemia increases [21].  Specifically, the SNP C677T has been 
studied in linking elevated levels of homocysteine to coronary artery disease and is one of the 
SNPs that are the focus of our study [22].  In previous studies, the major allele was C, and was 
observed ~56% of the time in a control population [23].  The C→T mutation causes an alanine to 
valine change, which results in a thermolabile product with reduced activity [24].  This could be 
a factor in the reduced efficacy of homocysteine detoxification.  Another commonly studied SNP 
on MTHFR which we will study is C1068T.  In previous studies, the major allele was C, and was 
observed ~86% of the time in a control population [25].  The C→T mutation is a silent change in 
the third base of the codon for Ser353.  This causes the loss of a Hha1 restriction site and could 
be related to the previously mentioned risks involved with SNPs in MTHFR [25].  A diagram of 
the MTHFR gene is shown in figure 2. 
 
 
Figure 2. Diagram of the MTHFR gene: exon and SNP location (C677T and C1068T)       
1.6.2 MS 
The MS gene, which encodes the enzyme methionine synthase, is also on chromosome 1, 
and is 105,244 base pairs long. The enzyme is sometimes also referred to as 5-
methyltetrahydrofolate-homocysteine methyltransferase, or MTR [26].  It catalyzes the final step 
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in methionine synthesis by producing enzyme that, in conjunction with the enzyme Methionine 
Synthase Reductase, or MTRR, catalyzes the methylene-THF to 5-methyl-THF reaction.  
Mutations in this gene have been shown to be associated with susceptibility to cleft lip/palate, 
Down syndrome, methylcobalamin deficiency, and neural tube defects [27].  A common SNP on 
this gene that has been studied, which we will also examine, is A2756G.  In previous studies, the 
major allele was A, and was observed in ~81% of a control population [23].  The A→G mutation 
results in a glycine to aspartic acid substitution and could adversely affect the final step in 
methionine synthesis, leaving the body with higher levels of toxic homocysteine [28].  Figure 3 
shows a diagram of the MS gene structure. 
 
Figure 3. Diagram of the MS (MTR) gene: exon and SNP location (A2756G)    
1.6.3 MTRR 
The MTRR gene, which encodes the enzyme Methionine Synthase Reductase, is located 
on chromosome 5, and is 32,020 base pairs long. The MTRR enzyme is responsible for 
producing enzyme that helps to regenerate Methionine Synthase [29].  This allows the process of 
detoxification of homocysteine to occur.  A common SNP on this gene that has been studied for 
its association with coronary artery disease is A66G [30].  In previous studies, the major allele 
was A, and was observed ~51% of the time in a control population [23].  The A→G mutation 
results in an isoleucine to methionine substitution, which could potentially cause the previously 
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mentioned conditions [31].  Figure 4 shows a diagram of the MTRR gene structure.  
 
Figure 4. Diagram of the MTRR gene: exon and SNP location (A66G) 
1.7 MACS COHORT STUDY  
The Multi Center AIDS Cohort Study (MACS) is an ongoing multi-location study, 
initiated in 1984, of the natural and treated histories of HIV-1 infection in homosexual and 
bisexual men.  The locations participating in the study include Baltimore, Chicago, Los Angeles, 
and Pittsburgh.  The study includes men who are HIV-seronegative, HIV-infected men who are 
not on HAART, and HIV-infected men who are on HAART.  The criteria for our investigation 
are that men must currently be enrolled in the MACS and they must have given a blood sample 
in the past year [1, 32].  These criteria are important because classifying men into high risk and 
low risk atherogenic phenotypes requires that clinical data and cholesterol data be collected from 
men enrolled in the study.  The following clinical information was obtained from the MACS 
participants, and were considered as variables during analysis: age, family history of CVD, race, 
fasting glucose, HbA1c, total cholesterol (TC), low-density lipoprotein-cholesterol (LDL), high-
density lipoprotein-cholesterol (HDL), triglycerides (TG), Apolipoprotein A, Apolipoprotein B, 
insulin, body mass index (BMI), HIV status, CDC-AIDS classification, date of AIDS onset, 
duration of HAART, and use of cholesterol-lowering drugs such as statins.     
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1.8 ATHEROGENIC PHENOTYPE 
The term “atherogenic phenotype” refers to observable blood serum characteristics 
describing the likelihood of developing arterial plaques and susceptibility to cardiovascular 
disease.  It is customary to categorize people as having a high risk or low risk atherogenic 
phenotype, which are sometimes also referred to as phenotype B and phenotype A, respectively 
[33].  A high risk atherogenic phenotype is illustrated through the presence of high levels of low 
density lipoprotein (LDL), high levels of triglycerides, and low levels of high density lipoprotein 
(HDL).  This phenotype has been associated in past studies with cardiovascular disease [2].  The 
low risk atherogenic phenotype is just the opposite, and can be illustrated through the presence of 
low levels of low density LDL, lower levels of triglycerides, and higher levels of HDL [33].  
LDL levels that are considered “high” are typically classified as above 160mg/dL and increase 
the risk of cardiovascular disease.  LDL levels that are less than 100mg/dL are considered to 
have a protective effect against cardiovascular disease.  HDL levels that are less than 50mg/dL 
are considered “low” and are a risk factor for cardiovascular disease.  HDL levels that are above 
60mg/dL are considered “high” and are protective against cardiovascular disease.  Triglyceride 
levels are considered high when they are over 500mg/dL and are risk factors while levels under 
150mg/dL are considered normal and are protective factors against cardiovascular disease [34].   
Individuals infected with HIV have historically been reported to experience problems 
with lipid metabolism.  Past studies have reported hypocholesterolemia and hypertriglyeridemia 
in HIV+ individuals, as well as peripheral fat wasting (lipodystrophy), central fat accumulation, 
and insulin resistance [3].  HAART therapy was developed to reduce viral load in the blood, but 
has appeared to take part in causing these side effects that lead to cardiovascular disease [4].  It is 
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thought that these side effects are more severe amongst those with high risk atherogenic 
phenotypes [35].    
1.9 HYPOTHESIS AND AIMS 
We hypothesize that Infection with HIV and HAART therapy exacerbates underlying 
genetic predispositions to cardiovascular disease.  The folate metabolism pathway may be an 
important component of this.  We intend to investigate this hypothesis by accomplishing the 
following two aims: 
1) Genetic characterization of members enrolled in the MACS. 
2) Statistical determination of whether a certain SNP characterization correlates with 
presence or absence of a high/low risk atherogenic phenotype. 
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2.0  METHODS AND MATERIALS 
2.1 STUDY OVERVIEW 
The object of this study was to generate and analyze folate metabolism genotype data for 
the MACS participants against their clinical atherogenic phenotype data to see if there was an 
association between having a high risk atherogenic phenotype and developing cardiovascular 
disease while undergoing HAART therapy.  In order to carry this out, genotype data was 
generated for each of the previously mentioned SNPs on MACS DNA samples.  After generating 
genotype data, analyses were performed through generation of box-and-whisker diagrams, the 
Kruskal-Wallis Test, the odds ratio test, and logistic regression analysis. 
2.2 GENERATING GENOTYPE DATA 
This was performed using a four step process that shall be referred to as a fluorescence 
polarization assay.  The four steps included PCR amplification, agarose gel verification, 
primer/dNTP degradation, and fluorescence polarization.  The DNA utilized in these steps had 
previously been extracted from blood samples donated by the MACS participants.  After 
extraction, they were diluted to levels of 5ng/μL by members of the Martinson lab.  
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2.2.1 PCR AMPLIFICATION 
Polymerase chain reaction amplification (PCR) is an in vitro process performed to 
amplify a desired segment of DNA.  PCR is performed by heating a reaction mixture containing 
many reagents, including DNA, until the DNA denatures and the two strands separate.  The 
mixture is then cooled and primers, which are small complementary DNA sequences to the 
segment to be amplified, anneal to the edges of the parent DNA strand.  The mixture also 
contains deoxyribonucleoside triphosphates (dNTPs) in excess, which are added onto the primer 
strand by a thermostable DNA polymerase.  We used Taq polymerase.  The DNA polymerase 
functions in adding the dNTPs downstream of the primer in a complementary manner to the 
parent DNA strand.  At the completion of this event, there are two brand new DNA strands 
annealed to the two parent DNA strands.  These steps are repeated and the DNA segment is 
amplified exponentially every cycle.  The reaction mixture also contains sterile deionized water 
(SDW), a buffer, and magnesium chloride to optimize reaction conditions.  Table 1 shows the 
exact amounts of reagents added. 
The 10X buffer, magnesium chloride, dNTPs, and Taq polymerase were all purchased 
from Sigma.  The dNTPs came in individual tubes of 2’-deoxyguanosine 5’-triphosphate 
trisodium, thymidine 5’-triphosphate sodium salt solution, 2’-deoxyadenosine 5’-triphosphate 
sodium salt solution, and 2’-deoxycytidine 5’-triphosphate disodium solution, and were mixed 
together in a 1:1:1:1 ratio to make the dNTP mixture.   
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Table 1. PCR Reagents 
Reagent Mixture for 1 well Mixture for 96-well plate 
DNA 1μL 96 μL 
10X Buffer 1 μL 100 μL 
MgCl2 1 μL 100 μL 
dNTPs 0.08 μL 8 μL 
Primer Mixture 0.1 μL 10 μL 
Taq Polymerase 0.04 μL 4 μL 
SDW 8 μL 800 μL 
 
 The primers were ordered from Integrated DNA Technologies and were received at an 
original concentration of 5ng/μL.  Their sequences can be found in Table 2.  They were diluted 
from their original state by adding 8μL of TE buffer to 1μL of the forward primer and 1μL of the 
reverse primer for each 96-well plate PCR reaction.  Eppendorf skirted twin.tec 96-well plates 
were used to carry out the PCR reaction.  As described above, 10μL of reaction mixture was 
administered into each well using an Eppendorf Multipipette Plus.  DNA, in 1μL aliquots, was 
added to each well using a Gene Mate 8-channel pipette from ICS Bio Express.  The 96-well 
plate was then sealed with a rubber mat and placed into an Eppendorf Mastercycler.   
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The following program was run for all plates involving primers MTHFR C1068T, MS 
A2756G, and MTRR A66G: 
1) 95.0° C for 2 minutes 
2) 95.0° C for 30 seconds 
3) 67.0° C for 30 seconds 
4) Temperature increases at  a rate of 3.0° C/s until 72.0° C is reached 
5) Steps 2-4 are repeated 13 times 
6) 95.0° C for 30 seconds 
7) 60.0° C for 30 seconds 
8) 72.0° C for 1 minute 
9) Steps 6-8 are repeated 21 times 
MTHFR C677T : 
1) 95.0° C for 2 minutes 
2) 95.0° C for 30 seconds 
3) 64.0° C for 30 seconds 
4) Temperature increases at a rate of 3.0° C/s until 72° C is reached 
5) Steps 2-4 are repeated 13 times 
6) 95.0° C for 30 seconds 
7) 57.0° C for 30 seconds 
8) 72.0° C for 1 minute 
9) Steps 6-8 are repeated 21 times 
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A different procedure was used for MTHFR C677T because better PCR results were obtained 
when a lower temperature was used for primer annealing (57.0° C).  The other primers 
performed best at 60.0° C.         
Table 2. Forward and Reverse PCR Primers, 5’→3’ 
Forward and Reverse PCR Primers, 5’→ 3’ 
SNPS Forward Reverse 
MTHFR 
C677T 
CATCCCTATTGGCAGGTTACCC  AACTCAGCGAACTCAGCACTCC  
MTHFR 
C1068T 
GGCACATCGAAGGCTCCAGTC TGACTCCTCCCAGGTCAACCAC 
MS 
A2756G 
GCTATCTTGCATTTTCAGTGTTCCC AATGATCCAAAGCCTTTTACACTCC 
MTRR 
A66G 
GGATCTTTTTTCCCCCATTTTTC CTTCCCAACCAAAATTCTTCAAAGC 
 
Once the PCR Mastercycler completed the program, the plate was removed from the machine so 
that the next step, agarose gel verification, could be performed. 
2.2.2 AGAROSE GEL VERIFICATION 
Agarose gel verification involved running the PCR product on a gel to verify the presence 
of PCR product.  It was a measure of success that the PCR reaction was completed successfully.  
In each 96-well plate, a column of positive controls and water blanks were included.  The liquid 
in these wells was removed and placed in an 8 strip PCR Tube Zipperstrip from Phenix Research 
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Products.  Dye composed of bromophenol blue, xylene cyanol, and ficoll-400 was added and the 
contents were loaded into a 2% agarose gel.  The gel was made by adding 4 grams of GenePure 
LE agarose to 200mL of TBE buffer.  This solution was heated until the agarose completely 
dissolved.  After cooling to slightly above room temperature, 10μL of ethidium bromide, a DNA-
binding fluorescent tag, was added.  Then the agarose mixture was poured into a gel encasement 
and left to solidify.  Once solidification occurred, the gel was loaded with the DNA product and 
placed into the GelXLPlus from LabNet International Inc.  100V of electricity was applied for 30 
minutes and the gel was photographed under a UV light.  Presence of fluorescently glowing 
bands verified the existence of PCR product and the experiment moved onto the primer/dNTP 
degradation step.    
2.2.3 PRIMER/dNTP DEGRADATION STEP 
This step is performed to rid the PCR product of excess dNTPs and primers that remain 
from the PCR Amplification step.  These can interfere with the fluorescence polarization step 
and must therefore be removed.  This is done by adding an additional reaction mixture to the 
PCR product including exonuclease to degrade free primers and shrimp alkaline phosphatase to 
degrade free dNTPs.  Table 3 shows the exact amount of reagents added. 
The 10X rApid alkaline phosphatase buffer and rApid alkaline phosphatase (1U/μL) were 
purchased from Roche and the exonuclease (20,000 U/mL) was purchased from New England 
BioLabs.  This reaction mixture was added in 10 μL aliquots to the PCR product in the 96-well 
plate using the Eppendorf Multipipette Plus. 
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Table 3. Degradation Step Reagents 
Reagent Mixture for 1 well Mixture for 96-well plate 
10X rApid Alkaline 
Phosphatase Buffer 
1 μL 100μL 
rApid Alkaline 
Phosphatase 
1 μL 100 μL 
Exonuclease 0.05 μL 5 μL 
SDW 8 μL 800 μL 
  
The 96-well plate was then placed in the Mastercycler and the following program was run: 
1) 37°C for 1 hour 
2) 85°C for 15 minutes 
During the first step, the exonuclease and rApid alkaline phosphatase were placed at a 
temperature at which they function optimally (37°C).  They degraded the free primers and free 
dNTPs respectively.  The second step was intended to raise the temperature high enough to 
denature the exonuclease and shrimp alkaline phosphatase (85°C) to ensure that they do not 
interfere with the following fluorescence polarization step.  Once the program was completed, 
the 96-well plate was removed from the Mastercycler in order to continue with the final 
fluorescence polarization step.  
2.2.4 FLUORESCENCE POLARIZATION 
Fluorescence polarization is a single base primer extension assay that uses a fluorescently 
tagged dideoxynucleotide chain terminator to classify the genotype of the SNP.  The primers for 
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this assay are designed to anneal immediately upstream of the base pair of interest for SNP 
classification.  The fluorescently tagged base pair is a dideoxynucleotide and halts further 
annealing after it incorporates into the SNP position.  The dye labeled terminator is then read and 
the allele present can be deduced.  The reading of the dye labeled terminator is possible due to 
the principle that when a fluorescent molecule is excited by plane polarized light, it emits 
polarized light in response.  The fluorescence polarization, or FP, recorded is proportional to the 
molecule’s rotational relaxation time.  This is the amount of time it takes the molecule to rotate 
68.5°.  When viscosity and absolute temperature of the solution are held constant, the FP is also 
directly proportional to molecular weight of the molecule occupying the SNP position.  It is 
expressed in a fluorescence ratio of the horizontal and vertical axes.  This allows differences in 
alleles at the SNP position to be identified.  Two fluorescent dyes are used in the assay and each 
is tagged to a different one of the two possibilities of alleles for the SNP.  When these alleles 
incorporate and the FP is recorded, the homozygous and heterozygous allele genotypes separate 
into different quadrants on the horizontal and vertical axis [36].  An example of this can be 
observed in Figure 5.  Tamra and R110 were dyes used to tag the A and G dideoxynucleotides, 
respectively.  When an FP was read that showed proportions of the molecular weight for two AA 
fluorescently tagged molecules, a data point was recorded in the upper left hand quadrant of the 
graph.  When an FP was read showing a proportional molecular weight for an A, tagged with 
Tamra, and a G, tagged with R110 dye, a data point was recorded in the upper right hand 
quadrant of the graph.  Similarly, a GG FP reading recorded a data point in the lower right hand 
quadrant of the graph.  The lower left hand cluster was a negative control and failed sample 
quadrant, which showed samples that failed to incorporate any fluorescent signal.  Failed 
samples were disregarded during analysis.   
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Figure 5. Data Results for Fluorescence Polarization Assay: Genotype Clusters 
Table 4 shows the exact amount of reagents used for the Fluorescence Polarization step: 
Table 4. Fluorescence Polarization Step Reagents 
Reagents Mixture for 1 well Mixture for 96-well plate 
Thermosequenase 10X Buffer 1μL 100μL 
Primer 1μL 100μL 
ddNTP mixture 0.05μL 5μL 
Thermosequenase 0.05μL 5μL 
SDW 8μL 800μL 
 
The Thermosequenase 10X Buffer and Thermosequenase DNA polymerase 
w/pyrophosphatase (4Un/μL) were purchased from USB Corporation.  The ddNTP mixture was 
composed of a 16:16:15:15:1:1 ratio of ddCTP:ddATP:ddGTP:ddTTP:R110G:tamraA.  The 
Upper left quadrant: 
DNA samples that are 
homozygous for the A 
allele (A/A) 
Upper right 
quadrant: DNA 
samples that are 
heterozygous (G/A) 
Lower right 
quadrant: DNA 
samples that are 
homozygous for the G 
allele (G/G) 
Lower left quadrant: 
DNA samples that are 
negative controls, 
samples that failed to 
be categorized. 
Tamra: Dye used to 
identify the A allele 
R110: Dye used to 
identify the G allele  
 
A/A G/A 
G/G Fail/ (-)control 
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ddGTP Ultrapure (10mM pH7.5), ddTTP Ultrapure (10mM pH 7.5), ddATP Ultrapure (10mM 
pH 7.5), and ddCTP Ultrapure (10mM pH 7.5) were purchased from USB Corporation.  Tamra 
ddATP (NEL 474 2.5Nmoles) and R110 ddGTP (NEL 495001 EA 2.5Nmoles) were purchased 
from Perkin Elmer Life Sciences Inc.  The primer was composed of 10μL of internal primer 
added to 100μL of 1X TE Buffer.  A table of internal primers is listed below.  The internal 
primers were purchased from Integrated DNA Technologies.  Forward and reverse internal 
primers were purchased for each SNP, however, we found that one primer typically gave higher 
quality results than the other.  Therefore we used the highest performing primer for each SNP.    
Table 5. Internal Primers for Fluorescence Polarization, 5'→ 3' 
Internal Primers for Fluorescence Polarization, 5’→3’ 
SNP Primer Orientation Internal Primer Sequence Fluorescent Dye 
MTHFR C677T Reverse Internal AAGCTGCGTGATGATGAAATCG A/G 
MTHFR 1068T Reverse Internal CCTCTCGGCGCTTGGGGTGGGC A/G 
MS A2756 Forward Internal GAATATGAAGATATTAGACAGG A/G 
MTRR A66G Forward Internal AAAGGCCATCGCAGAAGAAAT A/G 
 
 These reagents were mixed together and 10μL aliquots were placed into the 96-well 
plates using the Eppendorf Multipipette Plus.  The plates were then placed into the Mastercycler 
and the following program was run for all plates: 
1) 94.0°C for 1 minute 
2) 94°C for 10 seconds 
3) 52°C for 30 seconds 
4) Steps 2-4 are repeated 40 times 
5) 72°C for 10 seconds 
 23 
6) Temperature is held at 10.0°C until plate is removed from cycler 
When the plate was removed at the finish of the program, it was wrapped in foil to keep out 
any light that would prematurely excite the fluorescent dyes.  The plate was then taken to the LJL 
Biosystems Analyst HT where the fluorescently tagged ddNTPs were read.  The data collected were 
formatted into a graph as seen in Figure 5.     
2.3 STATISTICAL ANALYSIS 
The following methods were used in data analysis, and the statistical package, R (Lucent 
Technologies), was used to generate the plots and statistical calculations. 
2.3.1 BOX-AND-WHISKER DIAGRAMS 
Once all data were collected, box-and-whisker diagrams were generated to showcase the 
entire data set, and to enable observations of basic trends in the data.  A box-and-whisker 
diagram is a descriptive, non-parametric, method to showcase data.  It provides important 
information concerning the data set such as the median value and quartile locations of the data 
points.  In a box-and-whisker diagram, the horizontal, bold line represents the median.  This 
median line is surrounded by a box, which represents the middle 2 quartiles, or 50% of the data 
(Q2 and Q3).  The vertical lines are called whiskers.  The bottom whisker represents one half of 
Quartile 1 and the top whisker represents one half of Quartile 4.  Together the box and whiskers 
encompass 75% of the data.  Any data points residing outside of the box and whisker plot are 
extreme outliers and represent the data points that fall into the extreme high and low 12.5% of 
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the population.  On the box-and-whisker diagram that we generated, we inserted thin horizontal 
and dotted lines at threshold levels.  These were visual aids for identifying LDL, HDL, and 
triglyceride levels that were high or low.  These plots helped us to observe any obvious 
associations and helped to narrow our focus for the next statistical test.     
2.3.2 KRUSKAL-WALLIS TEST 
The Kruskal-Wallis Test is a conservative non-parametric test performed to observe the 
general shape of a distribution.  We used it so that we could observe the degree of equality 
amongst the population medians for SNPS C1068T and A2756G.  The nominal variable was the 
SNP classification and the measurable variable was the LDL level.  The test was performed to 
see if the LDL level difference was significant enough in each allele classification to result in a 
significant p-value.  This would indicate that one grouping of data points had significantly 
different median values than another grouping.  This would be strong evidence for an association 
between two variables.      
2.3.3 ODDS RATIO CALCULATION 
An odds ratio measures the size of the difference between populations by describing the 
strength of association between two binary values.  For this test, we compared genetic 
classification and LDL levels.  For the genetic classifications, AA and AG were grouped together 
into one category (the dominant inheritance group) and GG was the other category (the recessive 
inheritance group).  The LDL levels were classified as high (above 159 mg/dL) or not high 
(159mg/dL or lower).  If an odds ratio value of 1 is obtained, it describes no association between 
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the two variables.  We set up the calculation so that if an odds ratio value of greater than 1 is 
obtained, it describes the genotype GG as being a predictive factor for high LDL levels.  If a 
value of less than one is obtained for the odds ratio, GG is described as being a protective factor 
against high LDL levels, or a predictor of low LDL levels.  
 
2.3.4 LOGISTIC REGRESSION 
A logistic regression test was also performed.  This test allows prediction of the 
probability of an event by fitting data to a calculated logistic curve.  This is performed by 
quantifying the association between one or more independent variables and a binary response 
variable.  For this study, we used BMI, HIV status, HAART, and allele classification (AA, AG, 
GG) for C677T, C1068T, A2756G, and A66G as independent variables and high or not high 
LDL levels for the binary response variable.  LDL levels of above 159 were considered “high” 
and LDL levels of 159 and below were considered “not high.”   The statistics package, R was 
used for this [37]. 
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3.0  RESULTS 
A total number of 1,945 samples were typed for the four folate metabolism SNPs. Table 
6 summarizes the results obtained from the FP assays. 
Table 6. FP Assay Data Summary 
Locus Sample 
Size 
Minor Allele 
Frequency 
(MAF) 
Major Allele 
Homozygote 
Heterozygotes Minor Allele 
Homozygote 
MTRR A66G 1573 (A) 49.1% 914 (21.9%) 344 (58.1%) 315 (20.0%) 
MS A2756G 1730 (G) 19.8% 1127 (65.1%) 520 (30.1%) 83 (4.8%) 
MTHFR 
C1068T 
1565 (T) 6.90% 1358 (86.8%) 195 (12.5%) 12 (0.8%) 
MTHFR 
C677T 
1493 (T) 28.9% 806 (54.0%) 510 (34.2%) 177 (11.9%) 
 
Before beginning analysis, the racial background of the MACS participants was 
considered.  This is important because genetic differences among various racial groups can skew 
data.  Table 7 was generated, listing the genotypic data for the following self reported categories: 
whites, blacks, and other.  The other category was composed of various other races such as 
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Hispanic, Asian, and Native American.  Since the majority of the data was for the white 
category, all analysis beyond this table will be performed on that group in order to ensure the 
most consistent results.  
Table 7. Racial background summary of MACS participants 
Locus Race Major 
Allele 
Heterozygotes Minor 
Allele 
Blank/Fail HWE with 
Bonferroni 
correction 
MTHFR 
C677T 
White 259 197 75 129 0.041 
Black 225 49 2 53 0.984 
Other 42 35 27 26 -- 
MTHFR 
C1068T 
White 500 70 3 87 0.948 
Black 251 34 2 40 0.779 
Other 103 10 3 14 -- 
MTRR 
A66G 
White 94 343 144 79 *3x10-5 
Black 68 182 31 49 *7 x 10-6 
Other 24 67 16 23 -- 
MS 
A2756G 
White 421 162 29 48 0.041 
Black 170 126 20 14 0.870 
Other 78 37 5 100 -- 
 
In addition to listing the genotype data for each race, a Hardy Weinberg Equilibrium 
calculation with a Bonferroni correction was also performed for the white and black groups.  The 
Hardy Weinberg principle states that allele and genotype frequencies remain constant in a 
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homogenous population unless disturbed by non-random mating, mutations, selection, limited 
population size, "overlapping generations", random genetic drift and gene flow [38].  The 
number shown in the chart is the p-value.  P-values that are not significant are considered within 
Hardy Weinberg Equilibrium.  A Bonferroni correction was applied to the Hardy Weinberg 
Equilibrium to correct for Family wise Type I error that occurs when multiple independent 
comparisons are made [39].  This enables small amounts of error, involved in each comparison, 
to be corrected.  The correction involves dividing the Hardy Weinberg Equilibrium p-value by 
the number of independent comparisons that were made [39].  Since four SNP comparisons were 
made for both black and white races, this meant that there were 8 comparisons to consider.  The 
original p-value of 0.05 was therefore divided by 8.  After application of the Bonferroni 
correction, the p-value for each category was 0.00625.  All categories fell into Hardy Weinberg 
Equilibrium except for the MTRR A66G white and black categories, whose p-values remained 
more extreme than 0.00625.  This is most likely due to a complication in the assignment of 
genotypes for that particular SNP.  This will be further analyzed at a later date.  The other SNPs 
fell into Hardy Weinberg Equilibrium and their data will be used for additional analysis.  The 
Hardy Weinberg Equilibrium calculation was not performed for the “other” category because it 
was a heterogeneous group.  The results would not be significant since the conditions for the 
Hardy Weinberg Equilibrium principle do not apply to heterogeneous groups [38].   
Since the data involved several variables and the potential for their associations were 
very complex, we analyzed the data on several different levels.  A box-and-whisker diagram was 
made to observe any obvious associations between LDL, HDL, and total triglyceride levels 
versus each SNP’s genotype classifications. 
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Figure 6. HDL levels versus SNP genotype classifications of white samples 
As previously mentioned, high HDL levels (60mg/dL and above) are protective factors 
against cardiovascular disease and low HDL levels (50mg/dL or less) are risk factors.  The 
horizontal, solid black line in Figure 6 represents the high HDL level cutoff and the dotted 
horizontal line represents the low HDL level cutoff.  The thick horizontal line represents the 
median for the data set, the box represents 50% of the data set, and the whiskers encompass 75% 
of the data set.  The pictured data points are extreme outliers and show the most extreme 12.5% 
of the data set.  There are no obvious associations in Figure 6.  However, due to the complexity 
of variables involved, it is not expected to find a simple association at this point. 
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Figure 7. LDL levels versus genotype classification of white samples 
As previously mentioned, high levels of LDL (160mg/dL and above) are risk factors for 
CVD and low levels of LDL (100mg/dL and below) are protective factors.  The solid horizontal 
line in Figure 7 represents the high LDL level cutoff.  There appears to be a trend in MTHFR 
C1068T that the samples genotyped as TT have lower LDL levels than those with CT or CC 
genotypes.  There also appears to be a trend in MS A2756G that the samples genotyped as GG 
have lower LDL levels than those with AG or AA genotypes.  This will be further investigated 
with other statistical tests. 
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Figure 8. Total Triglyceride Levels versus genotype classification for white samples 
As previously mentioned, high levels of triglycerides (500mg/dL and above) are risk 
factors for CVD and low levels of triglycerides (150mg/dL and below) are protective factors.  
The dotted horizontal line in Figure 8 shows the 500mg/dL cutoff and the solid horizontal line 
shows the 150mg/dL cutoff.  There do not appear to be any obvious associations in this figure. 
Since LDL levels for SNPs C1068T and A2756G (Figure 7) were the only ones that 
showed a possible association with genotype, more descriptive box-and-whisker diagrams were 
developed for them.  The population was separated into individuals on HAART therapy and 
individuals not on HAART therapy.  The population of individuals not on HAART is made up of 
primarily individuals (n=583) not infected with HIV and is therefore meant to be a control group.      
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Figure 9.  LDL levels versus MTHFR C1068T genotypes for white samples 
              
Figure 10. LDL levels versus MS A2756G genotypes for white samples 
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In Figure 9, it initially appears that the TT genotype in the C1068T SNP is a protective 
factor for LDL levels, since all of the data points are below the 159mg/dL threshold.  However, 
since there was only one data point in that category, we cannot say if it is a significant result 
without conducting further tests.  However, in figure 10 there may be a positive association 
between individuals undergoing HAART therapy with the genetic characterization of GG for the 
A2756G SNP and low LDL levels.  There were 5 individuals in this category and we decided to 
investigate this possible association more thoroughly.    
Next the Kruskal-Wallis Test was performed.  Two degrees of freedom and a 95% 
confidence interval (CI) were used.  We found that the p-values were not significant (data not 
shown) indicating that there is no significant difference in the distributions of LDL levels 
between the three genotype groups overall. This test does not, however, consider the 159 mg/dL 
threshold of LDL cholesterol levels that distinguishes high cholesterol individuals from low 
cholesterol ones. 
We then performed an odds ratio calculation, as this enables us to consider the influence 
of genotype on the binary outcome of high LDL vs. non-high LDL.  A 95% CI was used for this 
test as well.  An odds ratio was calculated for the overall MS A2756G data, MS A2756G data for 
individuals on HAART therapy, and MS A2756G data for individuals not on HAART therapy.  
We expected to see a higher odds ratio in the HAART+ group than the HAART- group since we 
hypothesize that HAART in addition to HIV infection and genetic factors are related to high 
LDL levels.  For the overall data set, we found an odds ratio of 0.24 with a CI of 0.03-1.75.  For 
the HAART+ data set, we found an odds ratio of 0.49 with a CI of 0.06-3.82.  For the HAART- 
data set, we found an odds ratio of 0.22 with a CI of 0.01-3.66.  Although this suggests that the 
presence of the GG genotype at MS A2756G is associated with non-high LDL levels, in each 
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case the 95% CI included 1.0, so we cannot conclude that any of these results are statistically 
significant.  We suspect that this was due to the abnormally large CI caused by a small 
population for some of the genotype classifications.  The odds ratio was highest for the 
HAART+ data set (0.49) and, still being less than 1, shows a small association with low LDL 
levels.   
To further investigate how variables are influenced by A2756G SNP classification, we 
performed a logistic regression analysis.  None of the variables (BMI, HIV status, HAART 
status, or SNP classification) showed a significant p-value.  This means that individually, these 
variables do not predict LDL level classification.  However, the intercept p-value was significant 
(0.0139).  This means the data set as a whole may predict LDL level classification.    
Table 8. Summary of Logistic Regression p-values 
Variable z-value p-value 
Intercept -2.166 0.0303 * 
BMI 0.350 0.7261 
HAART  -0.976 0.3293 
C677T (C/T to C/C) 0.358 0.7201 
C677T (T/T to C/C -0.797 0.4252 
C1068T (C/T to C/C) -0.038 0.9694 
C1068T (T/T to C/C) -0.013 0.9898 
A66G (A/G to A/A) 0.163 0.8703 
A66G (G/G to A/A) 0.407 0.6844 
A2756G (A/G to A/A) 0.975 0.3296 
A2756G (G/G to A/A) -0.164 0.8701 
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4.0  DISCUSSION 
Although none of the statistical tests performed showed definitively significant 
associations, we still believe that the genetics of this metabolic pathway warrant further 
investigation. 
The Hardy Weinberg Equilibrium calculation with the Bonferroni correction in Table 7 
showed that the most normal data was for the MTHFR and MS SNPs.  Therefore, that data was 
considered more reliable than the data for the MTRR SNP, A66G.  For consistency, further 
calculations were performed on the white category, as it was the racial group of the highest 
prevalence in the data.  This was performed so any genetic variation between races could be 
eliminated.   
The box-and-whisker diagrams, shown in Figures 6, 7, and 8, show the entire set of 
genotype data generated versus HDL, LDL, and triglyceride levels.  We were looking for a linear 
trend in data points, showing a certain genotype with extreme levels of LDL, HDL, or 
triglycerides (high or low) and the LDL levels decreasing or increasing across the X axis.  If GG, 
for example, contained all data points with low LDL levels, AG contained slightly higher LDL 
levels, and AA contained high LDL levels, it would suggest that the GG genotype is protective 
against high levels of LDL.  There were no trends seen in any of the graphs for HDL or 
triglycerides.  However, we thought that there could potentially be an association between 
genotype classification and LDL levels for MTHFR C1068T and MS A2756G.  The TT 
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genotype for MTHFR C1068T showed low levels of LDL which increased for CT, and was 
highest for CC.  For MS A2756G, LDL levels were highest for the AA classification, decreased 
for AG, and were lowest for GG.  We therefore continued our analysis focusing on these two 
SNPs and the LDL variable. 
We then generated more descriptive box-and-whisker diagrams of MHFR C1068T and 
MS A2756G versus LDL levels in Figures 9 and 10, respectively.  Individuals undergoing 
HAART therapy were separated from the individuals not undergoing HAART therapy.  This was 
done so that we could observe any difference, to which HAART therapy contributed.  We 
continued to look for linear trends in LDL levels.  We also looked for a recessive inheritance 
trend.  For a trend like this, we would notice that low or high levels of LDL would only be 
observed for a homozygote phenotype.  For example, if GG was a recessive trait that predicted 
low LDL levels, the low levels would not be present in AG or AA.  Taking this into 
consideration, we also looked for any results that showed tight box-and-whisker groupings of 
homozygote data in either high or low positions in comparison to the other two groupings.  
Conversely, a dominantly inherited trend would show high or low LDL level groupings in both 
the heterozygote and dominant homozygote groupings.  In Figure 9, we observed a box and 
whisker grouping contained completely in the not high LDL level region for the genotype 
classification TT.  Initially it seemed as though this might have been a recessive inheritance 
trend.  However, the sample size for this classification was so small (n=1), it was likely that the 
trend was not significant.  In Figure 10, there was a box and whisker grouping contained 
completely in the not high LDL level region for MS A2756G GG.  The AA and AG samples had 
data points in the high LDL level region and the sample size for GG was 5.  We considered this 
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to be a significant number of data points and a possible recessive inheritance trend.  We then 
decided to pursue this possible association by performing more specific statistical tests.   
A Kruskal-Wallis test was performed next to quantify the extent of the trends we saw in 
the scatter plots and box-and-whisker diagram.  This test was performed for both C1068T and 
A2756G and no significant p-values were obtained.  This shows that there were also no 
statistically significant overall differences in LDL levels between the genotype classifications.  
However, this test is a conservative non-parametric test and it is possible that an association 
exists, but is too small to be detected by this general test.  This test was also performed to 
generally characterize the shape of the distribution without regard to LDL thresholds.  We next 
decided to address this by performing an odds ratio calculation. 
Since the box-and-whisker diagram showed A2756G as having a more promising data set 
for association, an odds ratio was calculated to see if GG was protective against high LDL levels.  
As mentioned in the results, the odds ratio showed a small association for this.  The CI was very 
large and prohibited us from being able to make a strong assertion that GG protected against high 
LDL levels.  The CI was very large due to the small sample size of individuals that were 
classified as having a GG genotype for the SNP A2756G.  While we think that there might be a 
stronger association between GG and hot high LDL levels, we cannot confidently state this until 
we have data for a larger sample size of individuals homozygous for the G allele.  This could 
easily be attained in a few weeks time.  The Center of Analysis for the Multicenter AIDS Cohort 
Study (CAMACS) keeps a library of clinical data for all of the MACS participants.  We 
collaborate with them by sending them genotypic data for these participants in exchange for the 
clinical data.  They have been unable, so far, to send us data for a large number of samples that 
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we have already genotyped.  Once these data, comprising ~800 additional samples, are received, 
our calculations can be revised and possibly statistically significant results will be obtained. 
The last statistical calculation that we performed was logistic regression.  This test 
enabled us to consider the possible effect of several different variables on high/not high LDL 
levels.  Once again, none of the individual p-values were significant, but the intercept p-value 
was significant.  The intercept p-value is the value of the logit score when all independent 
variables have a value of zero.  This estimates the degree of non-randomness in the dependent 
variable.  If data collected for the dependent variable differs from data expected when a random 
sampling is undertaken, then the p-value will be significant.  The significant p-value that we 
found suggests that there truly is a trend in this data set that can be considered predictive for 
LDL level classification.  Although none of the independent variables that we tested proved to be 
the cause of this significance, there could be other variables that were outside the scope of this 
study that caused the significant intercept p-value.  From the other plots and statistics we have 
generated, we believe that homozygous G alleles for A2756G are protective against high levels 
of LDL.  This, however, would not be directly observed in logistic regression.  In order for the 
A2756G p-value to be significant, the entire A2756G data set would have to correlate with low 
LDL levels.  Logistic Regression would probably not detect one subgroup that influences LDL 
levels.  The lack of sensitivity of this statistical test is a disadvantage, but it is useful in enabling 
the observation of several variables and their predictive abilities for a binary factor.             
 The folic acid metabolic pathway is a very influential part of the body’s biochemistry 
that has been associated, repeatedly, with CVD.  Although the specific mechanism has not been 
discovered, it is clearly a complex pathway, and host genetics influence it in a way that is still 
not fully understood.  When the variables of HIV infection and HAART are also considered, the 
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complexity increases.  A recently published paper in the journal of Acquired Immune Deficiency 
Syndromes has made an association between elevation of plasma homocysteine levels and 
HAART, therefore reinforcing our idea that the folic acid metabolic pathway is associated with 
HAART and CVD in HIV+ individuals [40].  Despite the fact that our study has not resulted in 
statistically significant associations, this conclusion can still be considered an important result.  
The elimination of MTHFR C677T, MTHFR C1068T, MS A2756G, and MTRR A66G as 
strongly causative factors leads us in pursuit of other SNPs in the folic acid metabolic process 
that may be involved, and to find associations that have yet to be discovered.   
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